Menu Content/Inhalt
Search  
Home
We transform your molecule into a registered drug
Debiopharm Group is a Swiss-based global bio-pharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs. Oncology is the group’s main area of expertise. In addition, Debiopharm Group develops or co-develops drugs for specific indications in the following therapeutic areas: infectious diseases, neurodegenerative disorders, cardiovascular diseases, pain, metabolic diseases and immune-mediated diseases.

Debiopharm Group’s core activities consist in:

  • Licensing-in new molecules presenting potentially superior therapeutic properties. This takes place following a robust search and evaluation process;
  • Taking the licensed-in molecules through the entire development process, i.e. pre-clinical and clinical development, formulation, manufacturing and registration;
  • Selecting the best licensee(s) for the worldwide commercialisation of the registered drugs.

Debiopharm Group has developed extensive expertise in other areas by carrying out:

  • Applied research in the field of peptides, e.g. to develop molecules with an enhanced safety and/or efficacy profile;
  • Drug delivery research, for instance to facilitate the administration of drugs to patients suffering from Alzheimer’s disease or patients in developing countries for whom a daily pill or a daily injection may not be practical;
  • Life-cycle management from a relatively early stage;
  • Industrial manufacturing involving the company’s own proprietary technology. It can be noted that Debiopharm Group has FDA-approved clinical scale-cGMP manufacturing facilities.

In addition, Debiopharm Group has been involved in the field of companion diagnostics since 2008, with a view to progressing in the area of personalised medicine.

Debiopharm Group has funded a chair at the EPFL in Lausanne and grants each year three scientific awards: two in Switzerland (EPFL and Haute Ecole valaisanne), and one in Japan (JCA Mauvernay Award).

Debiopharm Group has a team of 300 professionals from over 20 different countries; and it is advised by a network of international consultants with scientific expertise in all relevant areas.

Debiopharm Group invests in the molecules that it licences in while bearing the entire financial risk of the development process. Debiopharm Group’s main source of income consists in royalty payments, part of which is shared with the originators of the molecules.

Debiopharm Group has successfully brought five products to market, namely:

  • Eloxatin®, a DACH platin for the treatment of colorectal cancer. The active substance of this drug is oxaliplatin;
  • Decapeptyl®/Trelstar®/Pamorelin® - 1-month formulation. An LHRH agonist for the treatment of prostate cancer, endometriosis and precocious puberty. The active substance of this drug is triptorelin.
  • Decapeptyl®/Trelstar®/Pamorelin® - 3-month formulation;
  • Decapeptyl® - 6-month formulation;
  • Moapar®/Salvacyl® 3-month, an LHRH agonist for the treatment of sexual deviations. The active substance of this drug is triptorelin.

 

Debiopharm Group's latest achievements include but are not limited to partneship with Pfizer and with Novartis, which illustrate the complementarity between the leading pharmaceutical partners and Debiopharm Group.


Debiopharm Group was founded in 1979 and is headquartered in Lausanne, Switzerland.